Navigation Links
NCPA Statement on Bogus PCMA Study About Cost to Fix Medicare Part D
Date:11/30/2007

ALEXANDRIA, Va., Nov. 30 /PRNewswire-USNewswire/ -- The Pharmaceutical Care Management Association (PCMA) has released a study falsely claiming that pending legislation requiring prompt payment of Medicare Part D prescription drug claims will cost billions of dollars. PCMA represents 10 pharmacy benefit managers (PBMs), the corporate middlemen who administer prescription drug plans. In response, Bruce Roberts, RPh, executive vice president and CEO of the National Community Pharmacists Association (NCPA), issued the following statement:

"PCMA's newly-released, so-called study barely passes the laugh test. In it, PricewaterhouseCooper appears to have been commissioned to obtain information from five PBMs to determine if paying pharmacies on time will affect their profitability. You get what you pay for, and since the study's objective was to highlight the supposed cost of prompt payment compliance, the results were predictably supportive of that premise. Throwing out these bogus numbers as a way of scaring Congress is both desperate and really undermines what little credibility the PBM industry ever had.

"The intent of the Medicare Part D prescription program was not for PBMs to aggressively exploit the lack of reimbursement timing standards. The Medicaid program is able to reimburse pharmacies in a timely fashion without its administrative cost swelling. Why would prompt payment create such a financially onerous administrative hassle for the multi-billion dollar, publicly-traded PBMs, who surely have the capability to make the adjustment? While their earnings soar, community pharmacies are experiencing a financial crunch that was pivotal in causing five percent of these small businesses to close in 2006 -- the first year the program was put in place -- after years of stability. PBM profiteering is causing a patient access problem.

"Passing H.R. 1474 in the House and S. 1954 in the Senate is the right thing to do and the prospects for action before Congress adjourns this year are good. Community pharmacies want to be able to serve their Part D patients in the best way possible, but PBMs reimbursement practices make that increasingly more and more challenging and should end no matter how many number-fudging studies they tout."

To learn more about a truly independent study that demonstrates the severity of the Part D reimbursement problem go to: http://www.ncpanet.org/pdf/leg/ut_study_exec_sum_090607.pdf

The National Community Pharmacists Association, founded in 1898, represents the nation's community pharmacists, including the owners of more than 23,000 pharmacies. The nation's independent pharmacies, independent pharmacy franchises, and independent chains dispense nearly half of the nation's retail prescription medicines. To learn more go to http://www.ncpanet.org.


'/>"/>
SOURCE National Community Pharmacists Association
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Olympic Gold Medalist Marion Jones-Thompson Pleads Guilty to Making False Statements in Two Separate Federal Criminal Investigations
2. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
3. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
4. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
5. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
6. Statement by Oscar S. Wyatt, Jr.
7. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
8. Pelosi Statement on Proposed Entitlement Task Force
9. Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement
10. Statement on House/Senate Agreement on SCHIP Legislation
11. Statement from the Alliance for Quality Nursing Home Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... country’s leading private owners, developers and operators of commercial real estate proudly announced ... its 2015 Heart Health initiative. Team members portfolio-wide will continue Olshan Properties’ ...
(Date:5/4/2016)... MD (PRWEB) , ... May 04, 2016 , ... ... Ostomy and Continence Nurses (WOCN) Society™ and Canadian Association for Enterostomal Therapy ... event promotion, time saving and planning tools to attendees and exhibitors for the ...
(Date:5/4/2016)... Gilmer, TX (PRWEB) , ... May 04, 2016 ... ... commencement of a master charity program created to assist the people of their ... working closely with nonprofit organizations and community leaders. Their hope is to bring ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... 2016. SS&A teamed up with one of the top website design companies to ... contains informative legal articles related to the law firm's main practice areas. These ...
(Date:5/4/2016)... ... 2016 , ... Nordic Naturals announces another breakthrough innovation—Omega Curcumin, ... synergistic combination of omega-3 fatty acids and potent antioxidants contains 1000 mg concentrated ... and 200 mg of N-Acetylcysteine (NAC). , Each nutrient plays a distinct ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... 2016 According to market research ... Growth and Demand Forecast to 2022 - Industry Insights ... Field, Very High Field, Low to Mid Field, and ... Spine, Musculoskeletal, Vascular, Breast, Pelvic and Abdomen, Cardiac, and ... (MRI) market was valued at $5,351.7 million in 2015, ...
(Date:5/3/2016)... Norgine B.V. und ... entscheidenden Meilenstein durch diese Veröffentlichung zur  Hepatischen ... um Patientenresultate  bei Verdauungs- und Lebererkrankungen zu ... Verständnis der Hepatischen Enzephalopathie bei und hebt ... Enzephalopathie in der Öffentlichkeit zu schaffen und ...
(Date:5/2/2016)... 2016  Celsion Corporation (NASDAQ: CLSN ), ... from the first cohort of patients in its ... Study) combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... In the first three patients dosed, GEN-1 plus ...
Breaking Medicine Technology: